IDEAYA Biosciences surges after eye cancer drug combo improves survival in trial

IDEAYA Biosciences

13/04/2026 15:15

Updates

** Shares of drug developer IDEAYA Biosciences IDYA.O rise 23.9% to about three month high of $37.80

** Stock set for its biggest pct. gain in nearly three years, if gains hold

** Co says its experimental combination drug developed in collaboration with French drugmaker Servier to treat a type of aggressive eye-cancer met the main goal in a mid-to-late-stage study

** Uveal melanoma is a rare form of eye cancer that has spread to other parts of the body

**  The drug, darovasertib, in combination with Pfizer's PFE.N Xalkori, improved survival by a median of 6.9 months versus 3.1 months for other therapies chosen by the trial's investigator

** The companies say they plan to apply for accelerated approval of the combination to the U.S. Food and Drug Administration in the second half of 2026

** As of last close, IDYA stock was down 11.8% YTD

 (Reporting by Padmanabhan Ananthan and Kamal Choudhury)

 ((Padmanabhan.Ananthan@thomsonreuters.com))